{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:09:09Z","timestamp":1777702149946,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Interferon &amp; Cytokine Research"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>\n                    A previous report on 814 patients who were coronavirus disease 2019 (COVID-19) positive provided preliminary therapeutic efficacy evidence with interferon-\u03b12b (IFN-\u03b12b) in Cuba, from March 11 to April 14, 2020. This study re-evaluates the effectiveness of IFN-\u03b12b during the period from March 11 to June 17, 2020. Patients received a combination of oral antivirals (lopinavir\/ritonavir and chloroquine) with intramuscular or subcutaneous administration of IFN-\u03b12b. The primary endpoint was the proportion of patients discharged from the hospital; the secondary endpoint was the case fatality rate, and several outcomes related to time variables were also evaluated. From March 11 to June 17, 2,295 patients had been confirmed to be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive in Cuba, 2,165 were treated with Heberon\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Alpha R, and 130 received the approved protocol without IFN. The proportion of fully recovered patients was higher in the IFN-treated compared with the non-IFN-treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. Benefits of IFN were significantly supported by time variables analyzed. This second report confirmed our preliminary evidence about the therapeutic effectiveness of IFN-\u03b12b in SARS-CoV-2 infection and postulated Heberon Alpha R as the main component within antiviral drugs used in the Cuban protocol COVID-19.\n                  <\/jats:p>","DOI":"10.1089\/jir.2020.0188","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T15:54:50Z","timestamp":1608306890000},"page":"578-588","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery"],"prefix":"10.1177","volume":"40","author":[{"given":"Ricardo","family":"Pereda","sequence":"first","affiliation":[{"name":"Intensive Medicine Department, Medical College of Havana, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Pedro Kouri Institute, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert Blas","family":"Rivero","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Rivero","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Miguel Enr\u00edquez Surgical Clinical Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albadio","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Enrique Cabrera General Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissette Del Rosario","family":"Lopez","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Juan Manuel Marquez Pediatric Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Mezquia","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Miguel Enr\u00edquez Surgical Clinical Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Venegas","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Luis D\u00edaz Soto Central Military Hospital, Havana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio Roberto","family":"Betancourt","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Manuel Piti Fajardo Surgical Clinical Military Hospital, Villa Clara, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo Emilio","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Intensive Medicine Department, Octavio de la Concepcion y la Pedraja Military Hospital, Camag\u00fcey, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Nodarse","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Center for Genetic Engineering and Biotechnology, Habana, Cuba."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.34172\/jre.2021.05","article-title":"Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program","volume":"7","author":"Abdo-Cuza A","year":"2021","unstructured":"Abdo-Cuza A, , Castellanos-Guti\u00e9rrez R, , Treto-Ramirez J, , Arencibia-Larin S, , G\u00f3mez-Pariente T, , Gonz\u00e1lez-Fern\u00e1ndez T, , Hern\u00e1ndezPerera JC, , Arocha-Stalella K, , Verdecia-Gorrita N, , Vento-Buigues L, , Cordero-Vasallo Y, , Rivero-Yi Y, , Gonz\u00e1lez-Dias O, , Nodarse-Cuni H, , Machado-Mart\u00ednez R, , Blanco-Gonz\u00e1lez MA, , Valdivia-Arencibia J, , Mendez-Felipe D, , Delgado-Almora E, , Guti\u00e9rrez-Guti\u00e9rrez C, , Su\u00e1rezL\u00f3pez J, , Leiva-Torres JL, , Rodr\u00edguez-Sotolongo A, , Bejerano-Gil N. 2021. Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. J Renal Endocrinol, 7:e05.","journal-title":"J Renal Endocrinol"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00221-18"},{"issue":"20","key":"e_1_3_5_4_1","first-page":"30164","article-title":"Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?","volume":"1359","author":"Aric\u00f2 E","year":"2020","unstructured":"Aric\u00f2 E, , Bracci L, , Castiello L, , Gessani S, , Belardelli F. 2020. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?. Cytokine Growth Factor Rev, S1359\u2013S6101(20):30164\u201330167.","journal-title":"Cytokine Growth Factor Rev"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_3_5_6_1","first-page":"10","article-title":"A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19","author":"Belhadi D","year":"2020","unstructured":"Belhadi D, , Peiffer-Smadja N, , Yazdanpanah Y, , Mentr\u00e9 F, , Laou\u00e9nan C. 2020. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv. [Epub ahead of print];, DOI: 10.1101\/2020.03.18.20038190. 2020.03.18.20038190.","journal-title":"medRxiv. [Epub ahead of print];"},{"key":"e_1_3_5_7_1","doi-asserted-by":"crossref","unstructured":"Carrillo-Larco RM. 2020. COVID-19 data sources in Latin America and the Caribbean. Travel medicine and infectious disease 101750. Advance online publication. https:\/\/doi.org\/10.1016\/j.tmaid.2020.101750.","DOI":"10.1016\/j.tmaid.2020.101750"},{"issue":"1","key":"e_1_3_5_8_1","first-page":"35","article-title":"Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B","volume":"32","author":"Casta\u00f1eda C","year":"2002","unstructured":"Casta\u00f1eda C, , Garc\u00eda E, , Gr\u00e1 B, , Nodarse-Cun\u00ed H, , Garc\u00eda W, , Andrade M, , Mart\u00ednez G, , Trujillo M, , Soto G, , Amoroto M, , Viada C, , L\u00f3pez-Saura P. 2002. Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B. Acta Gastroenterol Latinoam, 32(1):35\u201342.","journal-title":"Acta Gastroenterol Latinoam"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/107999099313352"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1998.00103.x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00304-9"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.03.006"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.013679"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"issue":"4","key":"e_1_3_5_18_1","first-page":"e7560","article-title":"A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"Kakodkar P","year":"2020","unstructured":"Kakodkar P, , Kaka N, , Baig MN. 2020. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus, 12(4):e7560.","journal-title":"Cureus"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591110-000000000-00000"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2097"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105924"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198074"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.07.982264"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15270"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104811"},{"key":"e_1_3_5_27_1","unstructured":"MINSAP (2020a). News. Cuban Ministry of Public Health. Available at www.sld.cu\/anuncio\/2020\/05\/11\/ministerio-de-salud-publica-protocolo-de-actuacion-nacional-para-la-covid-19."},{"key":"e_1_3_5_28_1","unstructured":"MINSAP (2020b). COVID-19 daily report: Closing part of the day June 17 at 12 midnight June 18 2020. Cuban Ministry of Public Health. Available at https:\/\/salud.msp.gob.cu."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.05.002"},{"issue":"3","key":"e_1_3_5_30_1","first-page":"184","article-title":"Interferon alpha-2b and ribavirin as combined therapy for chronic hepatitis C in Cuba: national Program","volume":"29","author":"Nodarse-Cun\u00ed H","year":"2012","unstructured":"Nodarse-Cun\u00ed H, , Ar\u00fas-Soler E, , Rivera-Reim\u00f3n LL, , P\u00e9rez-Lorenzo M, , Samada-Su\u00e1rez M, , Garc\u00eda-Ferrera WO, , S\u00e1nchez-Rodr\u00edguez YA, , Pupo-Oliveros D, , Obreg\u00f3n-Moreno A, , Umpierre-Garc\u00eda I, , Mart\u00ednez-Mart\u00ednez O, , Moret-P\u00e9rez A, , Gonz\u00e1lez-Gonz\u00e1lez Y, , Berm\u00fadez-Hern\u00e1ndez Y, , Garc\u00eda-Iglesias E, , Lazo-Diago OC, , L\u00f3pez-Saura P, , Cuban Group for the study of liver diseases. 2012. Interferon alpha-2b and ribavirin as combined therapy for chronic hepatitis C in Cuba: national Program. Biotecnol Apl, 29(3):184\u2013188. ISSN 1027\u20132852.","journal-title":"Biotecnol Apl"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1258\/0022215042244741"},{"issue":"1","key":"e_1_3_5_32_1","first-page":"1211","article-title":"Cuban interferon alpha-2b","volume":"34","author":"Nodarse-Cuni H","year":"2017","unstructured":"Nodarse-Cuni H, , Lopez-Saura P. 2017. Cuban interferon alpha-2b. Thirty years as an effective and safe drug. Biotecnol Apl, 34(1):1211\u20131217.","journal-title":"Thirty years as an effective and safe drug. Biotecnol Apl"},{"key":"e_1_3_5_33_1","unstructured":"Pan American Health Organization (2020). PAHO COVID-19 Daily Update: 17 June 2020. World Health Organization. Available at https:\/\/www.paho.org\/en\/documents\/paho-covid-19-daily-update-17-june-2020 (last accessed June17 2020)"},{"key":"e_1_3_5_34_1","article-title":"Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience","author":"Pereda R","year":"2020","unstructured":"Pereda R, , Gonzalez D, , Rivero H, , Rivero J, , Perez A, , del Rosario Lopez L, , Mezquia N, , Venegas R, , Betancourt J, , Dominguez R. 2020. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. medRxiv, 2020.","journal-title":"medRxiv"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1818446"},{"key":"e_1_3_5_36_1","doi-asserted-by":"crossref","unstructured":"Radhakrishnan Arunkumar and Arunachalam Ruckmani and Elango Abinaya 2020. Critical Review and Analysis of Approval of Favipiravir for Restricted Emergency Use in Mild to Moderate COVID-19. Available at SSRN: https:\/\/ssrn.com\/abstract=3636958 or http:\/\/dx.doi.org\/10.2139\/ssrn.3636958.","DOI":"10.2139\/ssrn.3636958"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775"},{"key":"e_1_3_5_38_1","unstructured":"RPCEC. 2020a. Use of Heberon\u00ae Alfa R in patients confirmed for infection with SARS-CoV-2 in Cuba. Observational clinical study. (COVID-19). National Coordinating Center for Clinical Trials. Cuban Public Registry of Clinical Trials. Ministry of Public Health. Available at https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000318-En."},{"key":"e_1_3_5_39_1","unstructured":"RPCEC. 2020b. Pharmacodynamics and safety in healthy volunteers. National Coordinating Center for Clinical Trials. Cuban Public Registry of Clinical Trials. Ministry of Public Health. Available at https:\/\/rpcec.sld.cu\/en\/trials\/RPCEC00000308-Sp."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104791"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22276"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.3.443"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.369.6500.125"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05425-5"},{"key":"e_1_3_5_45_1","unstructured":"World Health Organization. (2020a). Coronavirus disease (COVID-2019) situation reports-149 17 June. World Health Organization. Available at https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"e_1_3_5_46_1","unstructured":"World Health Organization. (2020b). Coronavirus disease (COVID-2019) situation reports-173 11 July. World Health Organization. Available at https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"e_1_3_5_47_1","unstructured":"World Health Organization. (2020c). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance 28 January 2020. World Health Organization. Available at https:\/\/apps.who.int\/iris\/handle\/10665\/330893."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.11.20061473"},{"key":"e_1_3_5_50_1","first-page":"1","article-title":"Interferon-\u03b12b treatment for COVID-19","volume":"11","author":"Zhou Q","year":"2020","unstructured":"Zhou Q, , Chen V, , Shannon CP, , Wei XS, , Xiang X, , Xu W, , Wang ZH, , Tebbutt SJ, . Kollmann TR, , Fish EN. 2020. Interferon-\u03b12b treatment for COVID-19. Front Immunol, 11:1\u20136.","journal-title":"Front Immunol"}],"container-title":["Journal of Interferon &amp; Cytokine Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jir.2020.0188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2020.0188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2020.0188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:35:02Z","timestamp":1777455302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/jir.2020.0188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1089\/jir.2020.0188"],"URL":"https:\/\/doi.org\/10.1089\/jir.2020.0188","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.28.20157974","asserted-by":"object"}]},"ISSN":["1079-9907","1557-7465"],"issn-type":[{"value":"1079-9907","type":"print"},{"value":"1557-7465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}